MANGOCEUTICALS, INC. Files 8-K with Key Agreements and Asset Changes
Ticker: MGRX · Form: 8-K · Filed: Aug 4, 2025 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Aug 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, acquisition, equity-sale
TL;DR
MANGOCEUTICALS, INC. 8-K: Material agreements, asset deals, and equity sales on July 30, 2025.
AI Summary
On July 30, 2025, MANGOCEUTICALS, INC. reported the entry into a material definitive agreement, the termination of a material definitive agreement, and the completion of an acquisition or disposition of assets. The company also disclosed unregistered sales of equity securities and filed financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including material agreements and asset transactions, which could impact the company's future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, terminations, and asset transactions, which inherently carry business and financial risks.
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- July 30, 2025 (date) — Date of Earliest Event Reported
- 15110 N. Dallas Parkway , Suite 600 Dallas , Texas 75248 (address) — Principal executive offices
FAQ
What specific material definitive agreements were entered into by MANGOCEUTICALS, INC. on July 30, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this summary.
What was the nature of the material definitive agreement that was terminated by MANGOCEUTICALS, INC.?
The filing states that a material definitive agreement was terminated, but the specifics of this termination are not detailed in the provided text.
Can you describe the acquisition or disposition of assets completed by MANGOCEUTICALS, INC.?
The filing confirms the completion of an acquisition or disposition of assets, however, the details of the transaction are not elaborated upon in this excerpt.
What type of equity securities were sold on an unregistered basis by MANGOCEUTICALS, INC.?
The filing mentions unregistered sales of equity securities, but the type and details of these securities are not specified.
What financial statements and exhibits were filed by MANGOCEUTICALS, INC.?
The filing indicates that financial statements and exhibits were submitted, but the content of these documents is not described here.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding MANGOCEUTICALS, INC. (MGRX).